EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Assessment of Spillover of Antimicrobial Resistance to Untreated Children 7–12 Years Old After Mass Drug Administration of Azithromycin for Child Survival in Niger: A Secondary Analysis of the MORDOR Cluster-Randomized Trial

Brittany Peterson iD, Ahmed M Arzika, Abdou Amza, Ramatou Maliki, Alio Mankara Karamba, Mariama Moussa, Mariama Kemago, Zijun Liu, Eric Houpt, Jie Liu, Suporn Pholwat, Thuy Doan und 4 weitere

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciae267 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Brittany Peterson und 15 weiteren Autor:innen. Beteiligte Einrichtung: Francis I. Proctor Foundation, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Azithromycin, Anti-Bacterial Agents, Mass Drug Administration, Drug Resistance, Bacterial. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The risk of antibiotic resistance is complicated by the potential for spillover effects from one treated population to another. Azithromycin mass drug administration programs report higher rates of antibiotic resistance among treatment arms in targeted groups. This study aimed to understand the risk of spillover of antibiotic resistance to nontarget groups in these programs.

Methods

Data were used from a cluster-randomized trial comparing the effects of biannual azithromycin and placebo distribution to children 1–59 months old on child mortality rates. Nasopharyngeal samples from untreated children 7–12 years old were tested for genetic determinants of macrolide resistance (primary outcome) and resistance to other antibiotic classes (secondary outcomes). Linear regression was used to compare the community-level mean difference in prevalence by arm at the 24-month time point, adjusting for baseline prevalence.

Results

A total of 1103 children 7–12 years old in 30 communities were included in the analysis (15 azithromycin, 15 placebo). The adjusted mean differences in the prevalence of resistance determinants for macrolides, β-lactams, and tetracyclines were 3.4% (95% confidence interval, −4.1% to 10.8%; P = .37), −1.2% (−7.9% to 5.5%; P = .72), and −3.3% (−9.5% to 2.8%; P = .61), respectively.

Conclusions

We were unable to demonstrate a statistically significant increase in macrolide resistance determinants in untreated groups in an azithromycin mass drug administration program. While the result might be consistent with a small spillover effect, this study was not powered to detect such a small difference. Larger studies are warranted to better quantify the potential for spillover effects within these programs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzithromycinAnti-Bacterial AgentsMass Drug AdministrationDrug Resistance, BacterialHumansChildFemaleMaleNigerChild MortalityChild, PreschoolInfantNasopharynxMacrolides

Stichwörter der Autor:innen

Nigerantimicrobial resistanceazithromycinmass drug administrationspillover

Substanzen

AzithromycinAnti-Bacterial AgentsMacrolides

Autor:innen und Institutionen

  • Francis I. Proctor Foundation, University of California, San Francisco, California, USA.
  • Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
  • Centre de Recherche et Interventions en Santé Publique, Birni N'Gaoure, Niger.
  • Programme Nationale de Santé Oculaire, Niamey, Niger.
  • Division of Infectious Diseases & International Health, University of Virginia, Charlottesville, Virginia, USA.
  • School of Public Health, Qingdao University, Qingdao, China.

ORCID-Profile: Brittany Peterson, Kieran S O'Brien

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • Gates Foundation
  • National Institute of Allergy and Infectious Disease
  • Bill & Melinda Gates Foundation
  • National Institutes of Health

Zitieren

APA

Peterson, B., Arzika, A. M., Amza, A., Maliki, R., Karamba, A. M., Moussa, M., Kemago, M., Liu, Z., Houpt, E., Liu, J., Pholwat, S., Doan, T., Porco, T. C., Keenan, J. D., Lietman, T. M., & O'Brien, K. S. (2024). Assessment of Spillover of Antimicrobial Resistance to Untreated Children 7–12 Years Old After Mass Drug Administration of Azithromycin for Child Survival in Niger: A Secondary Analysis of the MORDOR Cluster-Randomized Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae267

Vancouver

Peterson B, Arzika AM, Amza A, Maliki R, Karamba AM, Moussa M, et al. Assessment of Spillover of Antimicrobial Resistance to Untreated Children 7–12 Years Old After Mass Drug Administration of Azithromycin for Child Survival in Niger: A Secondary Analysis of the MORDOR Cluster-Randomized Trial. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae267

BibTeX
@article{Peterson2024,
  author = {Peterson, Brittany and Arzika, Ahmed M and Amza, Abdou and Maliki, Ramatou and Karamba, Alio Mankara and Moussa, Mariama and Kemago, Mariama and Liu, Zijun and Houpt, Eric and Liu, Jie and Pholwat, Suporn and Doan, Thuy and Porco, Travis C and Keenan, Jeremy D and Lietman, Thomas M and O'Brien, Kieran S},
  title = {Assessment of Spillover of Antimicrobial Resistance to Untreated Children 7–12 Years Old After Mass Drug Administration of Azithromycin for Child Survival in Niger: A Secondary Analysis of the MORDOR Cluster-Randomized Trial},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciae267}
}
Kostenlos starten →